“O.itemList.length” “- this.config.text.ariaShown
“This.config.text.ariaFermé”
JERUSALEM, August 13, 2020 / PRNewswire / – KAHR Medical announced the company’s participation in the Oppenheimer’s Private Life Sciences Company’ series of calls, which will run almost August 17-19, 2020.
Yaron Pereg, Ph.D., chief executive of KAHR Medical, was invited to provide a review of the company’s fusion protein generation and its leading clinically developed anti-CD47 candidate developed for counterfeit tumor remedy.
Details of the company’s presentation include:
Event: Oppenheimer Corporate Life Sciences Call Series Date: Monday, August 17, 2020 Time: 12:15 p.m. ET – 12:50 p.m. ET
About DSP107
DSP107 targets tumors that overexpress CD47, block signs of macrophage inhibitor, and deliver a sign of immune coestimulation to express activated tumor antigen T cells. CD47 is overexpressed in many cancer cells and BINDs SIRP to immune phagocytic cells to produce a “don’t eat me” sign. DSP107 binds CD47 to cancer cells, blocking interaction with SIRP and thus blocking the “Don’t Eat Me” sign. Simultaneously, DSP107 binds to 41BB in T cells, stimulating their activation. These activities lead to targeted immune activation through the destruction of tumors mediated by macrophages and T cells. Recently, the U.S. Food and Drug Administration legalized an application for a new experimental drug (IND) for DSP107. As a component of this IND, the company intends to launch a Phase I/II clinical trial to compare the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of DSP107 alone and in mixture with Roche’s PD-L1 blocking control point inhibitor (IPC). atezolizumab (Tecentriq®) in patients with complex forged tumors. The review will be conducted at several centers in the United States and site activation activities are currently underway. The exam will be conducted as part of a clinical collaboration with Roche.
About KAHR Medical
KAHR Medical is the next generation of immuno-oncology drug applicants for the remedy of various types of cancer. Its patented generation allows the design of targeted biological drugs generated by merging the active extracellular domain names of a TNF-SF ligand and a type I membrane protein. These dual signaling proteins (DSPs) have two functional extremes, which can block and/or activate various biological reinforcement signals resulting in a synergistic result. The unique composition of DSP ensures lens activation and increased strength by assembling a superior multimeric protein arrangement that is essential to activate the TNF receiver family. The company’s investors are Flerie Invest AB, Oriella Limited, a subsidiary of Consensus Business Group Limited, HBL, Pavilion Capital, Mirae Asset, Korean Investment Partners and DSC Investments. For more information, visit https://kahr-medical.com/.
Company contact: Tsipi Haitovsky Global Media Liaison KAHR [email protected]
View content: http://www.prnewswire.com/news-releases/kahr-medical-to-present-at-oppenheimers-private-life-sciences-company-call-series-301111548.html
SOURCE KAHR Medical